Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry.

Affiliation

Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: [Email]

Abstract

The COMBO stent (OrbusNeich Medical, Ft. Lauderdale, Florida) is a new-generation bio-engineered drug eluting stent, combining an abluminal coating of a bioabsorbable polymer matrix for sustained release of sirolimus and luminal anti-CD34 coating for endothelial progenitor cell capture and rapid endothelialization.

Keywords

COMBO drug eluting stent,Dual therapy stent,Percutaneous coronary intervention,Target lesion failure,